Century-old drug offers new hope for autism treatment
- TA Clinical & Research newsletter for professionals – Issue 2 out!
- Century-old drug offers new hope for autism treatment
- Autism charity calls for better medical care for people “left in pain or to die prematurely”
- Our latest publication is out: Identifying and Managing Seizures in Autism
- Treating Autism coming to Basildon, ESSEX
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- May 2016
- April 2016
- March 2016
- October 2015
- June 2015
- November 2014
- September 2014
- June 2014
- January 2014
- June 2013
- March 2013
- March 2012
- January 2012
- November 2011
- October 2011
- September 2011
- June 2011
- May 2011
- March 2011
- September 2010
Groundbreaking research has identified a potential new treatment for the core symptoms of autism.
Results released today from an N of One: Autism Research Foundation supported small clinical trial in boys with autism may represent one of the most dramatic advances in autism yet. The findings offer both a new view of what autism is and the possibility of the first drug to treat its core symptoms.
“On a Saturday about a week after the infusion, his dad was making a snack in the kitchen. My son (14 years old, non-verbal) went in and said very clearly the first sentence of his life. He looked at his dad and said, “I want to eat chips.”
The encouraging results from the double-blind, placebo-controlled trial that tested the 100-year-old drug, suramin, were published yesterday in the Annals of Clinical and Translational Neurology. In the trial, conducted by Dr. Robert Naviaux at the University of California San Diego School of Medicine, 10 boys ages 5-14 years were given either a single dose of the drug suramin or a placebo. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all 5 boys who were give the active treatments. Those improvements were not seen in any of the children who received a placebo.
Suramin was developed in 1916 to treat African trypanosomiasis, also known as sleeping sickness. It is administered intravenously and is currently only available in hospitals for treating sleeping sickness disease. In order for this drug to become available to the wider autism community, its effects need to be confirmed and optimal dosage and safety protocols established in bigger studies and tested on large numbers of individuals.
The researchers are hoping to start the next phase of their research as soon as possible, but their ability to do so will depend on how soon they can raise the much need funds.
The total cost of the just-published small trial on 10 children was $1.2 million. Some of this was met through private donations, with a shortfall of $500,000.
“This work is new and this type of clinical trial is expensive,” (Dr Naviaux) said. “We did not have enough funding to do a larger study. And even with the funding we were able to raise, we had to go $500,000 in debt to complete the trial.”
In order to start the next phase on the trial, which would involve 40 children and adolescents with autism with different levels of severity, Dr Naviaux’s lab is urgently looking to raise $2 million.
Link to lab donations page: http://naviauxlab.ucsd.edu/support/
Naviaux R.K, Curtis B., Li K., et al. (2017) Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. doi:10.1002/acn3.424.
Cheng N., Rho J.M., & Masino S.A. (2017) Metabolic Dysfunction Underlying Autism Spectrum Disorder and Potential Treatment Approaches. Front Mol Neurosci. Feb 21;10:34. doi: 10.3389/fnmol.2017.00034.
Naviaux J.C., Schuchbauer M.A., Li K., et al. (2014) Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. Jun 17;4:e400. doi: 10.1038/tp.2014.33.
Naviaux J.C., Wang L., Li K., et al. (2015) Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. Mol Autism. Jan 13;6:1. doi: 10.1186/2040-2392-6-1.
Naviaux R.K. (2014) Metabolic features of the cell danger response. Mitochondrion. May;16:7-17. doi: 10.1016/j.mito.2013.08.006.